LErafAON

liposome-encapsulated antisense oligodeoxyribonucleotide 5'-GTGCTCCATTGATCG-3' that acts as both a multidrug resistance inhibitor and radiosensitizer; Oligonucleotides, Antisense being a D27 term is not allowed by the system as HM

Networked: 8 relevant articles (0 outcomes, 6 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Gokhale, Prafulla C: 7 articles (01/2009 - 11/2002)
2.	Kasid, Usha N: 7 articles (01/2009 - 11/2002)
3.	Zhang, Chuanbo: 6 articles (01/2009 - 11/2002)
4.	Pei, Jin: 4 articles (01/2009 - 11/2002)
5.	Ahmad, Imran: 4 articles (02/2006 - 11/2002)
6.	Dritschilo, Anatoly: 4 articles (02/2006 - 11/2002)
7.	Kumar, Deepak: 3 articles (01/2007 - 11/2004)
8.	Rahman, Aquilur: 3 articles (05/2004 - 11/2002)
9.	Newsome, Joseph T: 2 articles (01/2009 - 11/2002)
10.	Rudin, Charles M: 2 articles (02/2006 - 11/2004)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2009 - "The toxicology, pharmacokinetics, biodistribution, target selectivity, and anti-tumor efficacy studies of md-LErafAON were conducted in mice. " 03/01/2004 - "Present studies demonstrate enhanced tumor growth inhibition or regression in response to a combination of a chemotherapeutic drug and LErafAON. " 03/01/2004 - "The aim of this study was to examine the effect of combination of LErafAON and a chemotherapeutic agent on growth of human prostate (PC-3) and pancreatic tumor xenografts in athymic mice (Aspc-1 and Colo 357). " 11/01/2002 - "These data have formed a basis of the clinical Phase I studies of LErafAON for cancer treatment." 01/01/2007 - "Therapeutic benefit of a combination of LErafAON and radiation or an anticancer drug exceeds radiation or drug alone against human prostate, breast, and pancreatic tumors grown in athymic mice. "
2.	Thrombocytopenia (Thrombopenia) 11/01/2004 - "Dose-independent hypersensitivity reactions and dose-dependent thrombocytopenia limited tolerance of LErafAON. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 03/01/2004 - "Combination of LErafAON (i.v., 25 mg/kg/dose, x10/13) with gemcitabine (i.v., 75 mg/kg/dose, x4/6) also caused a significant tumor growth inhibition in the two pancreatic carcinoma models studied (Aspc-1: LErafAON+gemcitabine versus gemcitabine, p<0.0001, n=7; Colo 357: LErafAON+gemcitabine versus gemcitabine, p<0.002, n =5). "
4.	Hypersensitivity (Allergy) 11/01/2004 - "Dose-independent hypersensitivity reactions and dose-dependent thrombocytopenia limited tolerance of LErafAON. "
5.	Carcinoma (Carcinomatosis) 05/01/2004 - "LErafAON (25.0 mg/kg i.v. x 10) displayed significant antitumor activity (P<0.05) when administered as a single agent in prostate (PC-3), lung (A549) and breast (MDA-MB 231) carcinoma models. "

Related Drugs and Biologics

1.	Antisense Oligonucleotides
2.	Paclitaxel (Taxol)
3.	Doxorubicin (Adriamycin)
4.	Liposomes (Liposome)
5.	Proteins (Proteins, Gene)
6.	Small Interfering RNA (siRNA)
7.	Epirubicin (Ellence)
8.	Oligonucleotides
9.	Oligodeoxyribonucleotides
10.	Mitoxantrone (Novantrone)

Related Therapies and Procedures

1.	Radiotherapy
2.	Intravenous Infusions
3.	Drug Therapy (Chemotherapy)